<DOC>
	<DOCNO>NCT01359969</DOCNO>
	<brief_summary>This open-label study conduct confirm safety , pharmacokinetic profile efficacy Ruconest dose 50 U/kg use treatment acute angioedema attack patient , 2 include 13 year age .</brief_summary>
	<brief_title>Safety Ruconest 2-13 Year Old Hereditary Angioedema ( HAE ) Patients</brief_title>
	<detailed_description />
	<mesh_term>Angioedema</mesh_term>
	<mesh_term>Angioedemas , Hereditary</mesh_term>
	<mesh_term>Complement C1 Inhibitor Protein</mesh_term>
	<criteria>From 2 include 13 year age Clinical laboratory confirm diagnosis HAE ( baseline C1INH activity &lt; 50 % normal ) Signed write informed consent ( parental permission ) sign legal guardian ( ) Clinical symptom acute HAE attack Onset eligible symptom within 5 hour moment medical evaluation determine eligibility occur Attack severity moderate great , rat investigator A diagnosis acquire C1INH deficiency ( AAE ) A medical history allergy rabbit rabbitderived product positive antirabbit epithelium ( dander ) IgE test</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>13 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Hereditary Angioedema</keyword>
	<keyword>HAE</keyword>
	<keyword>Angioedema</keyword>
	<keyword>Recombinant C1 Inhibitor</keyword>
	<keyword>rhC1INH</keyword>
	<keyword>Pediatrics</keyword>
</DOC>